SG11202103756XA - Extracellular vesicles for targeted therapies against myeloid-derived suppressor cells - Google Patents
Extracellular vesicles for targeted therapies against myeloid-derived suppressor cellsInfo
- Publication number
- SG11202103756XA SG11202103756XA SG11202103756XA SG11202103756XA SG11202103756XA SG 11202103756X A SG11202103756X A SG 11202103756XA SG 11202103756X A SG11202103756X A SG 11202103756XA SG 11202103756X A SG11202103756X A SG 11202103756XA SG 11202103756X A SG11202103756X A SG 11202103756XA
- Authority
- SG
- Singapore
- Prior art keywords
- extracellular vesicles
- targeted therapies
- suppressor cells
- derived suppressor
- therapies against
- Prior art date
Links
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 title 1
- 238000002626 targeted therapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862747982P | 2018-10-19 | 2018-10-19 | |
| PCT/US2019/057043 WO2020082005A2 (en) | 2018-10-19 | 2019-10-18 | Extracellular vesicles for targeted therapies against myeloid-derived suppressor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103756XA true SG11202103756XA (en) | 2021-05-28 |
Family
ID=70283167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103756XA SG11202103756XA (en) | 2018-10-19 | 2019-10-18 | Extracellular vesicles for targeted therapies against myeloid-derived suppressor cells |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210332386A1 (en) |
| EP (1) | EP3850104A4 (en) |
| JP (1) | JP2022505159A (en) |
| KR (1) | KR20210081362A (en) |
| CN (1) | CN113286826A (en) |
| AU (1) | AU2019362064A1 (en) |
| BR (1) | BR112021007287A2 (en) |
| CA (1) | CA3116886A1 (en) |
| IL (1) | IL282405A (en) |
| MX (1) | MX2021004470A (en) |
| SG (1) | SG11202103756XA (en) |
| WO (1) | WO2020082005A2 (en) |
| ZA (1) | ZA202102404B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220259617A1 (en) | 2019-06-13 | 2022-08-18 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| IL300001A (en) | 2020-07-24 | 2023-03-01 | Massachusetts Gen Hospital | Improved virus-like particles and methods of using them for administration to cells |
| KR102699871B1 (en) * | 2021-04-29 | 2024-08-29 | 주식회사 서지넥스 | Hepatocellular carcinoma specific targeting exosome composition as a drug anticancer delivery and use thereof |
| KR102620197B1 (en) * | 2021-04-30 | 2024-01-02 | 가톨릭대학교 산학협력단 | Colorectal cancer specific targeting exosome composition as a drug anticancer delivery and use thereof |
| KR102632530B1 (en) * | 2021-05-24 | 2024-02-02 | 가톨릭대학교 산학협력단 | Stomach cancer specific targeting exosome composition as a drug anticancer delivery and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0906421A1 (en) * | 1996-05-30 | 1999-04-07 | University Of British Columbia | Enhanced efficacy of liposomal antisense delivery |
| GB9914650D0 (en) * | 1999-06-24 | 1999-08-25 | Angyogene Pharmaceuticals Ltd | Chimeric proteins mediating targeted apoptosis |
| DK2419144T3 (en) * | 2009-04-17 | 2019-10-21 | Univ Oxford Innovation Ltd | Composition for the supply of genetic material |
| WO2011097480A1 (en) * | 2010-02-05 | 2011-08-11 | University Of Louisville Research Foundation, Inc. | Exosomal compositions and methods for the treatment of disease |
| US10308959B2 (en) * | 2013-01-18 | 2019-06-04 | Henry Ford Health System | Methods, systems, and compositions relating to MiRNA-146a |
| WO2015002956A1 (en) * | 2013-07-01 | 2015-01-08 | Ohio State Innovation Foundation | Exosome delivery system |
| US20160160181A1 (en) * | 2014-12-03 | 2016-06-09 | Capricor Thera[eitocs, Inc. | Processes for producing exosomes in reduced oxygen culture conditions |
| WO2016179417A2 (en) * | 2015-05-06 | 2016-11-10 | The University Of Utah Research Foundation | Exosome delivery of micrornas |
| GB2552774A (en) * | 2016-07-12 | 2018-02-14 | Evox Therapeutics Ltd | EV-Mediated delivery of binding protein-small molecule conjugates |
| US20180028600A1 (en) * | 2016-07-15 | 2018-02-01 | Korea Institute Of Science And Technology | Novel recombinant exosome and use thereof |
| GB2552473A (en) * | 2016-07-21 | 2018-01-31 | Evox Therapeutics Ltd | Surface decoration of extracellular vesicles |
| GB201809622D0 (en) * | 2018-06-12 | 2018-07-25 | Evox Therapeutics Ltd | Engineering extracellular vesicles for affinity purification |
-
2019
- 2019-10-18 SG SG11202103756XA patent/SG11202103756XA/en unknown
- 2019-10-18 EP EP19873830.4A patent/EP3850104A4/en active Pending
- 2019-10-18 AU AU2019362064A patent/AU2019362064A1/en active Pending
- 2019-10-18 MX MX2021004470A patent/MX2021004470A/en unknown
- 2019-10-18 BR BR112021007287-0A patent/BR112021007287A2/en not_active IP Right Cessation
- 2019-10-18 US US17/284,284 patent/US20210332386A1/en active Pending
- 2019-10-18 JP JP2021521099A patent/JP2022505159A/en not_active Ceased
- 2019-10-18 WO PCT/US2019/057043 patent/WO2020082005A2/en not_active Ceased
- 2019-10-18 CN CN201980080032.8A patent/CN113286826A/en active Pending
- 2019-10-18 CA CA3116886A patent/CA3116886A1/en active Pending
- 2019-10-18 KR KR1020217014377A patent/KR20210081362A/en not_active Ceased
-
2021
- 2021-04-13 ZA ZA2021/02404A patent/ZA202102404B/en unknown
- 2021-04-18 IL IL282405A patent/IL282405A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020082005A2 (en) | 2020-04-23 |
| AU2019362064A1 (en) | 2021-05-20 |
| CN113286826A (en) | 2021-08-20 |
| US20210332386A1 (en) | 2021-10-28 |
| MX2021004470A (en) | 2021-09-14 |
| KR20210081362A (en) | 2021-07-01 |
| BR112021007287A2 (en) | 2021-07-27 |
| CA3116886A1 (en) | 2020-04-23 |
| EP3850104A4 (en) | 2022-07-06 |
| WO2020082005A3 (en) | 2020-07-30 |
| ZA202102404B (en) | 2022-10-26 |
| IL282405A (en) | 2021-06-30 |
| JP2022505159A (en) | 2022-01-14 |
| EP3850104A2 (en) | 2021-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282405A (en) | Extracellular vesicles for targeted therapies against myeloid-derived suppressor cells | |
| IL277344A (en) | Extracellular vesicles comprising sting-agonist | |
| SG11202102357RA (en) | Combination therapies | |
| MA50086A (en) | BACTERIAL EXTRACELLULAR (EV) VESICLES | |
| EP3661556A4 (en) | SYNTHETIC EXTRACELLULAR VESICLES FOR NEW THERAPIES | |
| IL280658A (en) | Extracellular vesicles for inhalation | |
| DK3473301T3 (en) | FIRE EXTINGUISHER COVER FOR ELECTRIC VEHICLE | |
| IL246997A0 (en) | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) | |
| SG11202102688PA (en) | Surface modified extracellular vesicles | |
| EP3250706A4 (en) | Extracellular vesicles for agent delivery | |
| SG11202102377YA (en) | Combination therapies | |
| SMT202500028T1 (en) | Combination therapies | |
| GB2604071B (en) | New framework for few-shot temporal action localization | |
| ZA202102727B (en) | Immunoablative therapies | |
| SG11202008620VA (en) | Humanized rodents for testing therapeutic agents | |
| IL280851A (en) | Target-specific extracellular vesicles | |
| GB2589473B (en) | 2-slot inline block manifold system | |
| GB201812371D0 (en) | Battery monitor | |
| IL287370A (en) | Extracellular vesicles derived from activated car-t cells | |
| GB201612204D0 (en) | Method for temporal inter-view prediction and technical equipment for the same | |
| IL284241A (en) | Therapies for squamous cell carcinomas | |
| IL252302B (en) | Phospholipid preparations for the improvement of communication skills | |
| EP3215877A4 (en) | Electro-optically based network infrastructures for telecommunication systems | |
| HK40044473A (en) | Extracellular vesicles for inhalation | |
| HK40042867A (en) | Extracellular vesicles comprising sting-agonist |